RESEARCH

Investigating the role of signal transducer and activator of transcription 3 in feline injection site sarcoma

Cheng-Hsin Shih\(^1\), Yen-Chen Chang\(^1\), Yun-Chiang Lai\(^1\) and Hue-Ying Chiou\(^2\) *

Abstract

**Background:** Feline injection-site sarcomas (FISSs) are malignant mesenchymal tumors of different histotypes. The pathogenesis of FISS has been correlated with chronic inflammation, resulting in neoplastic transformation. Activation of the Janus kinase-signal transducer and activator of transcription 3 (STAT3) have been demonstrated to play a critical role in tumor development by regulating signaling pathways involved in cell proliferation, survival, metastasis, and angiogenesis in human medicine. To characterize the role of STAT3 in FISS, we first detected STAT3 and phosphorylated STAT3 in formalin-fixed and paraffin-embedded (FFPE) FISS tissues using immunohistochemical staining.

**Results:** STAT3 was detected in 88.9% (40/45) of FISS cases, and phosphorylated STAT3 was detected in 53.3% (24/45) of cases. However, the expression levels of both forms of STAT3 were not correlated with tumor grade. To study the role of STAT3 in tumor survival, two primary cells derived from FISSs of two cats exhibiting consistent immunophenotypes with their parental FFPE tissues were established. A dose-dependent inhibitory effect on cell proliferation was observed in both primary FISS cells treated with the STAT3 inhibitor, 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide.

**Conclusions:** The STAT3 may play an important role in the tumorigenesis of FISS and be a potential molecular therapeutic target for FISS.

**Keywords:** Feline injection site sarcoma, Chronic inflammation, STAT3

Background

Feline injection-site sarcoma (FISS) has been recognized worldwide for over 20 years. It was previously called vaccine-associated sarcoma and was first described in 1991 [1, 2]. It was first proposed that the majority of fibrosarcomas arose in vaccination sites. Histologically, these neoplasms were surrounded by characteristic inflammatory infiltrates of lymphocytes and macrophages containing foreign materials identical to those previously described in post-vaccinal inflammatory injection site reactions. By electron probe X-ray microanalysis, aluminum oxide, which is an adjuvant in many feline vaccines, was identified in the surrounding macrophages [3–8]. The term “vaccine-associated sarcoma” is no longer appropriate because, in addition to vaccines, injection of foreign materials, such as long-acting antibiotics, steroids [6], lufenuron [9], meloxicam [10], cisplatin [11], or even microchip [12] in the subcutis or muscle of a predisposed cat can induce a chronic inflammatory response and ultimately neoplastic transformation. Following the observations that the development of FISSs was not necessarily due to vaccination, the new term “injection site sarcomas” was considered more compatible with the condition and has since gained wide acceptance.

*Correspondence: hychiou@dragon.nchu.edu.tw

2 Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, 402 Taichung, Taiwan

Full list of author information is available at the end of the article
The etiology of FISSs remains obscure; however, the hypothesis of FISSs, which may arise at the injection site as a result of chronic inflammation, is generally accepted. Chronic inflammation is considered to be inflammation of prolonged duration and is a sequela of acute inflammation if there is a failure to eliminate the agent or substance that incites the process. It is characterized by infiltration of lymphocytes, plasma cells, and macrophages, accompanied by tissue necrosis and tissue repair, such as wound healing, fibrosis, and granulation formation [13]. The potential role of chronic inflammation in the development of FISSs has already been discussed in the past decade owing to its histopathological features of the presence of an infiltrate of lymphocytes and macrophages at the tumor periphery, and is reminiscent of a persistent inflammatory response. Additionally, FISSs are primarily composed of the proliferation of spindle cells immunohistochemically and ultrastructurally as fibroblasts and myofibroblasts, which play a major role in chronic inflammation and wound healing [8, 14]. Cellular factors that promote inflammation, such as acidic fibroblast growth factor (FGF-a) and basic FGF (FGF-b), create a favorable environment for the expression of oncogenes and subsequent development of tumors [14]. Expression of p53, FGF-b, and transforming growth factor-α have been reported in FISSs, indicating the participation of these proliferation factors in the pathogenesis [14]. FISSs are histologically similar to feline ocular post-traumatic sarcomas, suggesting a common pathogenesis of inflammation and wound healing in the development of these mesenchymal tumors [15].

The connection between tumorigenesis and inflammation is mediated via intrinsic and extrinsic pathways [16]. The extrinsic pathway is driven by inflammatory or infectious conditions that increase the risk of cancer, and the intrinsic pathway is driven by genetic alterations such as oncogene activation and/or inactivation of tumor-suppressor genes that cause inflammation and neoplasia. Both pathways interfere with tumor cells and induce the activation of several key transcription factors in tumor cells leading to tumor-associated inflammation, including nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3 (STAT3), and hypoxia-inducible factor 1α, impacting any stage of tumorigenesis, such as initiation, promotion, progression, and metastasis [17]. These transcription factors coordinate the production of inflammatory mediators, including chemokines, cytokines (mainly interleukin [IL]-1, tumor necrosis factor, and IL-6), prostaglandins, and cyclooxygenase 2 production by tumor cells. Cytokines activate the same key transcription factors in inflammatory, stromal, and tumor cells, resulting in the production of more inflammatory mediators and a cancer-related inflammatory microenvironment that triggers tumor growth and invasiveness [16, 17].

Among the transcription factors aforementioned, STAT3 and NF-κB are critical for tumor-related inflammation. A positive association between NF-κB activation and tumor-associated inflammation is evidenced by colitis-associated colon cancer and hepatitis-associated hepatocellular carcinoma in murine models [18, 19]. In our previous study, NF-κB expression was confirmed in FISS, and there were dose-dependent inhibitory effects on the growth of FISS primary cells treated with an NF-κB inhibitor [20]. Similar to NF-κB, STAT3 is a point of convergence for numerous oncogenic signaling pathways. Transient STAT3 activation is a critical determinant for the restoration of tissue integrity [21], wound healing, and ultimately the resolution of the immune response. STAT3 plays a key role in normal cell growth, such as embryogenesis, and is constitutively activated in approximately 70% of solid and hematological cancers in human medicine, and is involved in cell proliferation, survival, angiogenesis, and tumor-mediated immune evasion [22]. Augmented tumor cell-intrinsic STAT3 signaling activity promotes tumor progression as well as tumor-extrinsic immunosuppressive effects. It modulates the surrounding stromal and variable types of immune cells by stimulating the production of pro-inflammatory cytokines, suppressing the secretion of type I interferons and associated interferon response genes, and supporting immunosuppression [23]. STAT3-dependent feedforward signaling loops are formed, which further fuel tumor progression. In normal cells or under physiological conditions, the activation of STATs is rapid and transient because they are negatively regulated by several proteins such as suppressors of cytokine signaling and protein inhibitor of activated STAT [24, 25]. Conversely, aberrant and persistent activation of STAT3 was observed in both tumor cells and adjacent stromal and immune cells.

In veterinary medicine, STAT3 expression has been reported in canine, feline, and equine mammary gland tumors [26, 27], equine renal hemangiosarcoma [28], feline oral squamous cell carcinoma [29], canine diffuse large B-cell lymphoma [30], and feline injection-site sarcomas [31]. In a previous veterinary study, the nuclear positive rate of phospho-STAT3 (Tyr705) was 68.89% (31/45) in feline mammary gland tumors [32] and 48.1% (13/27) in feline oral squamous cell carcinoma (OSCC) [29]. In previous human studies, nuclear phospho-STAT3 (Tyr705) was immunoreactive in 37–67% of head and neck squamous cell carcinoma samples and 49.3% of hepatocellular carcinomas (HCC) [33]. Considering that FISS is regarded as a chronic inflammation-associated tumor with histological
features that are similar to wound healing, the expression of STAT3 may be significant and plays an important role in tumorigenesis.

STAT3 is highly expressed in FISS [31]. However, the expression level of phosphorylated STAT3, which is a prognostic factor in many human cancers [33–35], remains unknown in FISSs. This study aimed to characterize the expression of STAT3 and phosphorylated STAT3 (Tyr705) in FISSs and their derived primary cells and to investigate the role of STAT3 in FISS cellular survival using the STAT3 inhibitor LLL12. This study could enhance our knowledge of the sarcomagenesis of FISSs and might also identify potential therapeutic targets for FISS.

Results

Detection of STAT3 and phospho-STAT3 (Tyr705) expression and their correlation with histopathological grading in FISS cells by immunohistochemistry (IHC)

In this study, forty-five FISS cases diagnosed at our institute during the period of 2014 and 2018 were included. According to the soft tissue sarcoma grading system [36], 11.2% (5/45), 44.4% (20/45), and 44.4% (20/45) of the FISSs were graded as I, II, and III, respectively (Table 1). While there was no detectable STAT3 and phospho-STAT3 expression in the normal soft tissues surrounding FISSs, including skeletal and smooth muscles, adipose tissue, vessels, neuron, or connective tissues, our IHC staining revealed that approximately 88.9% (40/45) of the cases demonstrated cytoplasmic and/or nuclear positivity for STAT3 and 11.1% (5/45) of the cases were negative for STAT3 (score = 0) (Fig. 1). Cytoplasmic STAT3 expression with score 1, 2, and 3 were noted in 11.1% (5/45), 24.4% (11/45), and 53.3% (24/45) FISS cases, respectively; nuclear STAT3 expression with score 1, 2, and 3 were noted in 20% (9/45), 35.6% (16/45), and 26.7% (12/45) FISS cases, respectively. Approximately 82.2% (37/45) of the FISS cases showed cytoplasmic and nuclear double positivity for STAT3 (scores ranging from 1 to 3).

The phospho-STAT3 (Tyr705) expression was variable in the FISS tissues (Fig. 1); approximately 53.3% (24/45) of the cases showed nuclear positivity for phospho-STAT3 (Tyr705), and 46.7% (21/45) of the cases were negative for phospho-STAT3 (Tyr705) (score = 0) under IHC staining. Nuclear phospho-STAT3 (Tyr705) expression with score 1, 2, and 3 were noted in 28.9% (13/45), 17.8% (8/45), and 6.7% (3/45) FISS cases, respectively. According to Pearson’s correlation coefficient (r), the IHC scores of STAT3 and phospho-STAT3 (Tyr705) in FISSs were not significantly correlated with tumor grading, necrosis, and mitosis ($P > 0.05$).

Correlation of the immunophenotypes of the primary FISS cells with their corresponding formalin-fixed and paraffin-embedded (FFPE) samples

In total, primary FISS cells were successfully obtained from the eight FISSs. To correlate the immunophenotypes of the primary FISS cells with their corresponding original FFPE samples, immunocytochemical (ICC) and IHC using a panel of nine different antibodies were performed in the eight primary FISS cells and the corresponding FISS tissue sections, respectively. The results are shown in Fig. 2; Table 2. All primary FISS cells and their corresponding FFPE samples were positive for STAT3, NF-κB, and vimentin and negative for S100, Melan-A, and cytokeratin (CK). Based on these results, we confirmed that these primary FISS cells and FFPE samples were sarcomas of mesenchymal origin. Incompatible and variable staining results were observed for phospho-STAT3 (Tyr705), alpha-smooth muscle actin (α-SMA), and desmin. Most of the primary FISS cells and their corresponding FFPE samples were positive for α-SMA and negative for desmin, suggesting a myofibroblastic origin. Interestingly, most primary FISS cells were negative for phospho-STAT3 (Tyr705); however, their corresponding FFPE samples demonstrated immunoreactivity for phospho-STAT3 (Tyr705). Consistent ICC and IHC patterns were observed in the primary cells of FISS-10 and FISS-14 and their corresponding FFPEs. Both primary cells exhibited cytoplasmic STAT3 signals; however, different nuclear phospho-STAT3 (Tyr705) signals. These two primary cells were selected for in vitro LLL12 inhibition assays to compare the effects of LLL12 on FISS cells with or without nuclear phospho-STAT3 (Tyr705) signals. No detectable STAT3 and phospho-STAT3 expression was noted in the cultured feline normal tissue cells (Supplementary Fig. 2).

STAT3 inhibitor (LLL12) inhibits the proliferation of FISS cells with a dose-dependent effect

To assess the role of STAT3 in tumorigenesis, FISS-10 and FISS-14 primary cells exhibiting consistent ICC and IHC patterns with their corresponding FISS cells in FFPE were treated with the STAT3 inhibitor LLL12. Cell viability was evaluated using the AlamarBlue assay. Interestingly, LLL12 was able to inhibit the proliferation of both FISS-10 and FISS-14 primary cells in a dose-dependent manner (Table 3; Fig. 3A). Compared with the cells in the control group, significant growth inhibition was observed at a concentration of 0.125 μM in FISS-10 and FISS-14 cells with no obvious time differences at 24, 48, and 72 h of treatment. Normal feline soft tissue cells were treated with the same formula, and significant growth inhibition was observed only at a concentration of 10 μM in the
absence of a dose-dependent inhibitory effect (Fig. 3B). The IC\textsubscript{50} concentrations of FISS cells and normal feline soft tissue cells are shown in Table 4. Compared to the normal feline soft tissue cells with IC\textsubscript{50} values of 1.697 µM at 24 h of treatment and 1.665 µM at 72 h of treatment, both FISS-10 and FISS-14 cells exhibited greater
| Pathology number | Breed                  | Sex | Age (year) | Location    | Grading | STAT3<sup>b</sup> (cytoplasm/nucleus) | Phospho-STAT3<sup>b</sup> (nucleus) |
|------------------|------------------------|-----|------------|-------------|---------|--------------------------------------|------------------------------------|
| 1                | NTU2014-0003           | F   | 16         | Dorsal neck | III     | 3/3                                  | 0                                  |
| 2                | NTU2014-0015           | Mixed | Fsp 11     | Interscapula | III     | 3/2                                  | 1                                  |
| 3                | NTU2014-0246           | Mixed | Fsp 10     | Back        | II      | 3/3                                  | 2                                  |
| 4                | NTU2014-0398           | Mixed | Mc 9       | Back        | II      | 1/2                                  | 0                                  |
| 5                | NTU2014-0427           | Mixed | Fsp 11     | Right thigh | III     | 2/3                                  | 1                                  |
| 6                | NTU2014-0611           | Mixed | Mc 6       | Back        | III     | 3/3                                  | 1                                  |
| 7                | NTU2014-1505           | Persian | Fsp 8     | Interscapula | II      | 2/3                                  | 0                                  |
| 8                | NTU2014-1771           | Mixed | F 3        | Interscapula | II      | 2/2                                  | 0                                  |
| 9                | NTU2014-1978           | Persian | Fsp 13    | Back        | III     | 3/1                                  | 0                                  |
| 10               | NTU2014-2077           | Mixed | M 8        | Interscapula | II      | 3/3                                  | 0                                  |
| 11               | NTU2014-2752           | Mixed | Fsp 10     | Back        | I       | 1/1                                  | 1                                  |
| 12               | NTU2014-2758           | Mixed | Mc 10      | Interscapula | II      | 2/2                                  | 0                                  |
| 13               | NTU2014-2819           | Mixed | Fsp 10     | Back        | III     | 3/2                                  | 1                                  |
| 14               | NTU2014-2990           | Mixed | M 3        | Back        | III     | 1/2                                  | 1                                  |
| 15               | NTU2015-0387           | Mixed | Mc 10      | Back        | II      | 2/1                                  | 0                                  |
| 16               | NTU2015-0434           | Mixed | Fsp 11     | Left scapula | III     | 3/3                                  | 2                                  |
| 17               | NTU2015-0913           | Scottish Fold | Fsp 8    | Dorsal neck | II      | 0/0                                  | 0                                  |
| 18               | NTU2015-0942           | Mixed | Mc 5       | Back        | I       | 3/2                                  | 0                                  |
| 19               | NTU2015-1113           | Mixed | F 12       | Back        | III     | 1/1                                  | 0                                  |
| 20               | NTU2015-1101           | Mixed | Mc 11      | Back        | II      | 1/1                                  | 1                                  |
| 21               | NTU2015-1147           | Mixed | Mc 11      | Right scapula | II      | 0/0                                  | 0                                  |
| 22               | NTU2015-1180           | Mixed | Fsp 11     | Dorsal neck | I       | 2/3                                  | 1                                  |
| 23               | NTU2015-1522           | Mixed | Mc 7       | Right scapula | III     | 0/0                                  | 0                                  |
| 24               | NTU2015-1838           | Mixed | Fsp 8      | Back        | II      | 2/0                                  | 0                                  |
| 25               | NTU2015-1873           | Mixed | Mc 9       | Interscapula | II      | 3/2                                  | 0                                  |
| 26               | NTU2015-2125           | Mixed | Fsp 9      | Interscapula | II      | 3/2                                  | 0                                  |
| 27               | NTU2015-2312           | Mixed | Fsp 10     | Dorsal neck | I       | 3/2                                  | 0                                  |
| 28               | NTU2015-2410           | Mixed | M 8        | Back        | II      | 0/0                                  | 0                                  |
| 29               | NTU2015-2535           | Persian | F 12     | Back        | III     | 3/2                                  | 1                                  |
| 30               | NTU2015-3035           | Mixed | Fsp 12     | Interscapula | II      | 0/0                                  | 0                                  |
| 31               | NTU2015-3397           | Unknown | F 12     | Dorsal neck | II      | 3/2                                  | 2                                  |
| 32               | NTU2015-3449           | Mixed | Mc Unknown | Right scapula | II      | 2/1                                  | 1                                  |
| 33               | NTU2016-2413           | Mixed | Fsp 5      | Back        | I       | 3/2                                  | 2                                  |
| 34               | NTU2018-1819           | Mixed | Mc 10      | Back        | III     | 3/3                                  | 3                                  |
| 35               | NTU2018-1944           | Domestic short hair | Mc 7    | Left trunk  | III     | 3/3                                  | 3                                  |
| 36               | NTU2018-2134           | American short hair | Fsp 11 | Right scapula | III     | 3/2                                  | 1                                  |
| 37               | FISS-05                | Mixed | Mc 6       | Back        | I       | 3/1                                  | 0                                  |
| 38               | FISS-06                | Persian | Mc 9    | Back        | II      | 3/2                                  | 1                                  |
| 39               | FISS-07                | Mixed | Mc 5       | Right scapula | III     | 3/1                                  | 2                                  |
| 40               | FISS-08                | American short hair | Mc 10 | Neck        | III     | 3/1                                  | 1                                  |
| 41               | FISS-10                | Mixed | Fsp 10     | Left scapula | II-III  | 2/0                                  | 0                                  |
| 42               | FISS-12                | Domestic short hair | Fsp 9  | Left trunk  | III     | 2/0                                  | 2                                  |
| 43               | FISS-14 (NTU2018-1134) | Mixed | Mc 6       | Left trunk  | II      | 2/2                                  | 2                                  |
| 44               | FISS-15                | Domestic short hair | Mc 12 | Right elbow | III     | 3/3                                  | 2                                  |
| 45               | FISS-16                | Mixed | Mc 7       | Back        | II      | 3/3                                  | 3                                  |

<sup>a</sup> M Male; Mc, Male castrated; F, Female; Fsp Female spayed

<sup>b</sup> Count 10 HPF for each section (at least 1000 cells), 0 = negative; 1 = less than 10% cells positive; 2 = 10-50% cells positive; 3 = more than 50% cells positive
Fig. 2 The correlation of immunophenotypes of feline injection site sarcoma (FISS) cells in formalin-fixed and paraffin-embedded (FFPE) tissue sections by immunohistochemical (IHC) and the corresponding primary cells derived from FISS by immunocytochemical (ICC) staining. Images show the expression of panSTAT3 and phospho-STAT3 (Tyr705) in FFPE tissues of FISS-10 and FISS-14 and the corresponding derived primary cells (inset). The substitution of the primary antibody with antibody diluent was performed in the negative control. Scale bars = 50 μm; inset: scale bars = 50 μm

Table 2 The results of IHC and ICC profiles of different FISS primary cells and their corresponding FFPE specimens

|                | FISS-05 | FISS-06 | FISS-07 | FISS-08 | FISS-10 | FISS-12 | FISS-14 | FISS-17 |
|----------------|---------|---------|---------|---------|---------|---------|---------|---------|
| STAT3          | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| Phospho-STAT3 (Tyr705) | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| NF-κB p65      | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| α-SMA          | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| S100           | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| Melan-A        | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| CK             | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| Vimentin       | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |
| Desmin         | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     | +/-     |

* IHC immunohistochemistry, ICC immunocytochemistry, FFPE formalin-fixed and paraffin-embedded
* α-SMA alpha-smooth muscle actin
* NF-κB nuclear factor-kappa B
* CK cytokeratin
- = negative; + = more than 5% cells positive
vulnerability to the treatment. At 24 h of treatment (Table 4), the FISS-10 and FISS-14 cells had 5.6 and 3.4 fold lower IC50 values than those of normal soft tissue cells, respectively. The differences increased slightly to 7.7 fold and 3.7 fold lower IC50 values in FISS-10 and FISS-14 than those of normal soft tissue cells after 72 h of treatment, respectively. Accordingly, the FISS-10 cells were more sensitive to LLL12 treatment than the FISS-14 cells.

Inhibition of the migration of FISS primary cells by LLL12 using the wound healing assay
Since the FISS-10 primary cells exhibited the highest sensitivity to LLL12 treatment and a limited number of FISS-14 primary cells were collected, wound healing was performed in FISS-10 cells. A dose-dependent reduction in cell migration was observed under 0.25-2 µM of LLL12 treatment. Under 2, 1, and 0.5 µM LLL12 treatment, the migration distances of FISS-10 cells were reduced to 42.1–80% of the migration distance of DMSO-treated cells. Significant inhibition by LLL12 was detected at a concentration of 2 µM in FISS-10 primary cells (P < 0.05) (Fig. 4; Table 5). There was no significant inhibition at concentrations of 0.125, 0.25, 0.5, and 1 µM.

Table 3 The result of cell survival rate (% reduction of AlamarBlue) of different primary cells derived from feline injection site sarcomas (FISSs) following treatment with different concentrations of 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide (LLL12) for 1-3 days

| LLL12 (µM) | FISS-10 day 1 | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD |
|------------|---------------|------|----|------|----|------|----|------|----|------|----|------|----|
| 2          | 31.892        | 0.186|    | 23.754| 0.242| 32.665| 0.177| 11.279| 0.585| 17.964| 0.399| 14.257| 0.482|
| 1          | 37.898        | 0.594|    | 23.494| 0.151| 32.586| 0.160| 15.272| 0.580| 16.165| 0.297| 14.692| 0.244|
| 0.5        | 39.305        | 1.025|    | 25.812| 0.562| 34.366| 0.192| 41.122| 2.812| 69.744| 3.587| 57.243| 3.394|
| 0.25       | 60.345        | 1.347|    | 49.953| 0.939| 56.049| 0.736| 46.300| 14.753| 79.969| 16.165| 88.842| 3.645|
| 0.125      | 71.976        | 1.316|    | 67.882| 2.125| 90.040| 1.662| 62.514| 10.629| 139.298| 1.913| 109.572| 3.076|
| DMSO       | 122.028       | 1.679|    | 121.097| 3.457| 159.510| 4.100| 104.645| 6.453| 161.766| 3.668| 98.890| 22.530|
| 0          | 100.000       | 1.952|    | 100.000| 3.845| 100.000| 9.086| 100.000| 2.012| 100.000| 21.695| 100.000| 9.935|

Table 4 The IC50 of 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide (LLL12) for primary cells of feline injection site sarcoma (FISS) and feline normal soft tissues (FNST) following 24 or 72 hours of incubation

| Cell       | IC50 of LLL12 (µM) |
|------------|-------------------|
| FISS-10    | 0.2999            |
| FISS-14    | 0.5061            |
| FNST       | 1.697             |

of treatment. The inhibitory effects of LLL12 on cell proliferation were evaluated at 24, 48 and 72 h of LLL12 treatment by the Alamar Blue assay. DMSO was used for dissolving the LLL12 and was used as a vehicle control. Data are present as mean ± SD. *Statistically significant from the controls (P < 0.05)
Discussion

In the present study, the roles of STAT3 and phospho-STAT3 (Tyr705) in the tumorigenesis of FISSs were investigated. We have demonstrated that concurrent cytoplasmic and/or nuclear signals of STAT3 and nuclear signals of phospho-STAT3 (Tyr705) were detected in 82.2% and 53.3% of FISS cases, respectively. While the IHC scores of both STAT3 and phospho-STAT3 (Tyr705) in FISSs were not significantly correlated with tumor grading ($P > 0.05$), the high expression of both STAT3 and phospho-STAT3 (Tyr705) in FISSs suggests that disruption of the Janus kinase (JAK)-STAT3 signaling pathway may be a potential therapy for FISSs. Using two primary cells derived from FISSs (FISS-10 and FISS-14) showing consistent ICC and IHC patterns as their parental FFPE tissues, a dose-dependent inhibitory effect on the growth and migration ability of FISS cells after treatment with the STAT3 inhibitor LLL12 was confirmed. These results suggest that JAK-STAT3 signaling pathway may play an important role in the sarcomagenesis of FISS.

The expression of pan-STAT3 in FISSs has been demonstrated using pan-STAT3 antibody [31]. In a previous study, cytoplasmic STAT3 expression was detected in 83.33% (20/24) of cats treated with doxorubicin before surgery, and in 100% (15/15) of cats that received surgical treatment alone. Doxorubicin treatment has been suggested to significantly decrease STAT3 expression as compared with cases treated by surgery alone [31]. In the present study, we demonstrated a high cytoplasmic expression level of STAT3 in 88.9% of FISSs, which is similar to the previous research. Unfortunately, due to the current research is mainly based on a retrospective investigation and several limitations owing to the patient information was originally not designed to collect data for research, some information is bound to be missing. We are unable to track back the history of chemotherapy of all animals used in this study for better correlating the role of chemotherapy on STAT3 expression in FISS. In addition to the potential effect of doxorubicin
before surgery on the expression of STAT3 in FISS, factors such as individual variations of investigated animals in different studies and different procedures and conditions during FFPE preparation, such as post-mortem delay, fixation time, paraffin, storage time in paraffin, storage temperature, and age of the cut sections have been reported to influence the outcome of IHC [37] since most of FFPE tissue sections used in the present study were derived from tissue blocks collected during 2014 to 2018. Furthermore, regarding the pan-STAT3 antibody used for STAT3 detection could not differentiate STAT3 from phospho-STAT3 (Tyr705), in general, the majority of STAT3 located in the cytoplasm is in an inactive form [38, 39], and inactive STAT3 could also constitutively shuttle between the cytoplasm and nucleus [40]. Detection of phosphorylated STAT3 using western blotting confirmed antibody was performed in our study to specifically detect the activated form of STAT3. To our knowledge, this is the first report on the detection of phospho-STAT3 (Tyr705) in FISS. We demonstrated that 53.5% (24/45) of the cases expressed nuclear phospho-STAT3 (Tyr705) signals. There were more immunolabelled neoplastic cells at the periphery of the neoplasms than in the central region. This phenomenon may result from tissue necrosis in the central region. It is generally agreed that the formation of FISS is highly associated with chronic inflammation and wound healing. Therefore, the high expression of cytoplasmic STAT3 in FISS is reasonable because this transcription factor is commonly activated by cytokines of the IL-6 family, which are produced by macrophages and stromal fibroblasts during chronic inflammation [23].

Since STAT3 is involved in many different signaling pathways, interpretation of STAT3 activation is a complicated event. Herein, we focused on the JAK-STAT signaling pathway and, more specifically, the expression of phospho-STAT3 (Tyr705). Our results demonstrated that phospho-STAT3 was expressed in more than half of FISS cases. Phospho-STAT3 (Tyr705) expression is closely correlated with the histological grading and intratumor microvessel density in HCC [33]. Additionally, STAT3 activation is correlated with a better or worse prognosis depending on the tumor type [41]. The involvement of phospho-STAT3 (Tyr705) in cell proliferation, metastasis, and angiogenesis, and its correlation with prognosis in FISS cases warrant further investigation.

In our study, the expression of STAT3 and/or phospho-STAT3 (Tyr705) in FISSs did not correlate with tumor grading. These results differ from those of feline mammary gland tumors [27, 32]. Unlike FISSs, grading systems for feline mammary gland tumors [42] have been well studied. However, there are no widely accepted criteria for histological grading of FISS. We speculated that the failure to correlate the expression of STAT3 with the pathological grading in FISSs may be due to the soft tissue sarcoma grading system used in this and previous studies [20, 43–45] was inappropriate for FISS since most of the cases were graded as 2–3 due to the high score allocated for necrosis. The correlation between grading and recurrence was also not significant [44]. An appropriate grading system for FISS should be further modified by placing less emphasis on the necrosis score.

In this study, eight FISS-derived primary cells were established and demonstrated consistent positive immunoreactivity for STAT3, NF-κB, and vimentin; however, negative for S100, Melan-A, and CK with their corresponding FFPE samples. The cytopathological appearance of the FISS primary cells combined with diffuse strong vimentin reactivity supports a mesenchymal origin. The lack of immunoreactivity for S100, Melan-A, and CK excluded the neural crest, myoepithelial, melanocytic, and epithelial origins [46]. However, incompatible and variable results were observed for phospho-STAT3 (Tyr705), α-SMA, and desmin IHC/ICC staining. Many tumor cells that display constitutive STAT3 activation in vivo rapidly lose STAT3 phosphorylation once being placed in a culture medium without neighboring immune or stromal cells [47]. As the formation of phospho-STAT3 (Tyr705) requires chronic cytokine stimulation from neighboring stromal or inflammatory cells [38], the different in vitro and in vivo expression patterns of phospho-STAT3 (Tyr705) may result from different tumor microenvironments.

In the present study, all eight FISS-derived primary cells and their parental FFPE samples showed immunoreactivity for STAT3, NF-κB, and vimentin. Nuclear expression of NF-κB was detected in 83.3% of FISS cases in our previous study [20]. NF-κB and STAT3 control both distinct and overlapping groups of anti-apoptotic, pro-proliferative, and immune response genes during tumorigenesis. They cooperate to promote the development and progression of epithelial tumorigeneses, such as colon, gastric, and liver cancers [48]. Their high expression in FISS suggests that they may play an important role in chronic inflammation and tumor progression; however, the effects on the tumor, immune, and inflammatory cells, and the interactions of these two transcriptional factors require further investigation.

The two FISS-derived cells (FISS-10 and FISS-14) exhibiting consistent ICC and IHC patterns with their corresponding FFPE specimens were treated using the STAT3 inhibitor LLL12. A dose-dependent inhibitory effect was noted in both the FISS-derived primary cells treated with LLL12, while the inhibitory effect was absent in LLL12-treated feline normal soft tissue cells. LLL12 is a potent and selective inhibitor of STAT3 phosphorylation.
A computer model with docking simulation showed that LLL12 binds directly to the phosphoryl tyrosine 705 binding site of the STAT3 monomer [49]. These feline normal soft tissue cells were negative for STAT3, which may elucidate why they are not vulnerable to treatment. Similarly, normal canine osteoblasts are also comparatively resistant to the anti-proliferative effects of LLL12 [50]. LLL12 significantly reduces cell proliferation in three feline OSCC cell lines, and the most sensitive one correlates with the highest level of basal STAT3 phosphorylation [29]. However, in the present study, we failed to demonstrate a correlation between the expression level of phosphorylated STAT3 and cell sensitivity to the STAT3 phosphorylation inhibitor LLL12. We have demonstrated that the primary cells derived from both FISS−10 and FISS-14 were sensitive to LLL12 treatment regardless of STAT3 expression detected by IHC or ICC. Interestingly, we observed that the FISS-10-derived primary cells, which did not show immunoreactivity of phospho-STAT3 (Tyr705) in both IHC and ICC staining, were even more sensitive to LLL12 treatment than the FISS-14 primary cells. These results indicate that both FISS-derived primary cells are highly dependent on STAT3 signaling. To explain the result, we have performed western blotting, the more sensitive method than ICC and IHC, and demonstrated that STAT3 and phospho-STAT3 (Tyr705) were detected in comparable level in both FISS-10 and FISS-14 primary cells (Fig. 5). Since STAT3 is generally constitutively expressed, the absence of nuclear or phosphorylated STAT3 expression in FISS-10 might be due to the insensitivity of IHC and ICC. This may also be due to the natural dephosphorylation of nuclear phospho-STAT3 (Tyr705) [51] in FISSs or inappropriate specimen handling and slow fixation [52]. Our results suggest that western blot should always be included for characterize the expression level of STAT3 and phospho-STAT3 (Tyr705) in tumor cell studies.

Conclusions
Feline injection site sarcomas are aggressive neoplasms with the incidence about 1/1,000–10,000 in vaccinated cats. The high expression rates of STAT3 and phospho-STAT3 (Tyr705) in FISSs and the in vitro reduction in proliferation and tumor migration in FISS primary cells by the STAT3 phosphorylation (Tyr705) inhibitor in the present study suggest that the STAT3 may play an important role in the tumorigenesis of FISS and could be a potential therapeutic target for FISSs.
Methods

Case collection
A total of 45 clinical feline cases with a histological diagnosis of FISS referred to the Graduate Institute of Molecular and Comparative Pathobiology, National Taiwan University (NTU) from 2014 to 2018 were used in the present study. Data tabulated from the database were pathology number, breed, sex, age, tumor location, and sarcoma grading (Table 1). Histopathology slides and formalin-fixed and paraffin-embedded (FFPE) tissue sections were retrieved for this study.

Immunohistochemical staining for FFPE tissues
Four-micrometer-thick FFPE slides were deparaffinized using xylene, rehydrated with decreasing concentrations of ethanol, and rinsed with Tris-buffered saline, 0.1% Tween 20 (TBST). Antigen retrieval was performed by boiling the slides in an EDTA-based retrieval buffer (Trilogy™; Cell Marque, Rocklin, CA, USA) in a microwave (EZ-Retriever™ System; BioGenex Laboratories Inc., San Ramon, CA, USA) at 95 °C for 10 min. The slides were then incubated with 10% normal goat serum (Dako, CA, USA) at 95 °C for 10 min. The slides were finally counterstained with Mayor's hematoxylin (Leica Denmark A/S) for 3 min at room temperature. The slides from 1 to 3 for cell differentiation (1 = well-differentiated; 2 = poorly differentiated but with defined histotype; 3 = undifferentiated); mitotic rates (1 = less than nine mitoses per 10 high power fields; 2 = 10–19 mitoses per 10 high power fields; 3 = more than 20 mitoses per 10 high power fields), and necrosis (1 = no necrosis; 2 = necrosis in less than 50% of the total area; 3 = necrosis in more than 50% of the total area). Total scores ≥ 3 were designated as grade I; 4–6 were designated as grade II, and scores ≥ 6 were designated as grade III.

Histopathological and immunohistochemistry scoring criteria
A soft-tissue sarcoma grading system [36] was used for tumor grading in this study. The sarcomas were scored from 1 to 3 for cell differentiation (1 = well-differentiated; 2 = poorly differentiated but with defined histotype; 3 = undifferentiated); mitotic rates (1 = less than nine mitoses per 10 high power fields; 2 = 10–19 mitoses per 10 high power fields; 3 = more than 20 mitoses per 10 high power fields), and necrosis (1 = no necrosis; 2 = necrosis in less than 50% of the total area; 3 = necrosis in more than 50% of the total area). Total scores ≥ 3 were designated as grade I; 4–6 were designated as grade II, and scores ≥ 6 were designated as grade III.

Table 6 Primary antibodies, sources and dilutions

| Antibody     | Manufacturer code | Type/species          | Dilution |
|--------------|-------------------|-----------------------|----------|
| STAT3        | Cell Signaling    | Monoclonal/mouse      | 1:400    |
| Phospho-STAT3| Cell Signaling    | Monoclonal/rabbit     | 1:200    |
| NfκB p65     | Abcam ab86299     | Polyclonal/rabbit     | 1:200    |
| α-SMA        | Dako M0851        | Monoclonal/mouse      | 1:200    |
| S100         | Leica S100P-L-CE  | Polyclonal/rabbit     | 1:100    |
| Melan-A      | Leica MELANA-L-CE | Monoclonal/mouse      | 1:50     |
| Cytokeratin  | Genemed 61-0022   | Monoclonal/mouse      | 1:100    |
| Vimentin     | Leica VIM-V9-L-CE | Monoclonal/mouse      | 1:100    |
| Desmin       | Dako M0760        | Monoclonal/mouse      | 1:200    |

Table 7 Clinical data and pathological features of the 2 feline injection site sarcomas (FISSs) used for the establishment of primary cells

| FISS-10 | FISS-14 (NTU2018-1134) |
|---------|------------------------|
| Breed   | Mixed                  |
| Sex/Age | Mixed                  |
| Tumor size | 5/5                   |
| Location | 5/5                   |
| Pathological diagnosis | 1/5                   |
| Grading  | II                      |
| aIHC profile: bICC profile  | 2/2/2                  |
| cSTAT3  | 2/+                    |
| dPhospho-STAT3 (Tyr705) | 0/-/2+                 |

a IHC criteria: - = negative; + = more than 5% cells positive
b ICC criteria: count 10 HPF for each section (at least 1000 cells), 0 = negative; 1 = less than 10% cells positive; 2 = 10–50% cells positive; 3 = more than 50% cells positive
c IHC immunohistochemistry
d ICC immunocytochemistry
For IHC scoring, a semiquantitative method reported by Petterino et al. (2009) was modified and applied in this study. The tissue sections were evaluated by light microscopy to determine the anti-STAT3 and anti-phospho-STAT3 (Tyr705) positivity based on the cellular location of positive immunolabelling, cytoplasmic or nuclear for STAT3, and nuclear for phospho-STAT3 (Tyr705). Positive cells were counted in 10 high power fields (HPF) for each tissue section. At least 1000 cells were analyzed. Briefly, 0, absence of immunoreaction; 1, less than 10% positive cells; 2, 10–50% positive cells; and 3, more than 50% positive cells.

**Primary FISS cells isolation and cultivation**

To obtain the primary neoplastic FISS cell lines, wedge biopsies of masses developed at the injection site with a history of vaccination of cats were collected immediately after the surgery. For each case, a proportion of the mass was submitted for histopathological examination, and the remaining proportion was used for primary cell establishment. These cases were histologically confirmed as FISS. Explant culture was performed to establish primary FISS cells according to our previous study [20]. The tumor tissue was washed with phosphate-buffered saline (PBS) (Gibco, Grand Island, NY, USA)–3–4 times until the tissue became white in appearance, cut into numerous 1-mm³ fragments, and placed into a 75T sterile tissue culture flask (Corning, Corning, NY, USA) containing 15 mL of Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 20% fetal bovine serum (FBS, Gibco) 250 ng/mL Amphotericin B, 100 U/mL Penicillin, and 100 µg/mL Streptomycin (Gibco). Regarding the primary normal feline soft tissue, small pieces of soft tissues including fibrous connective tissue and skeletal muscle remote from the tumor site were aseptically removed and cut into small fragments. The tissues were washed with PBS (Gibco)–3–4 times and then digested with 0.05% trypsin (Gibco) for 10 min. The suspended pellet mixture was filtered through a pre-wet 100 µm strainer (CORNING) and the supernatant was collected, centrifuged, and re-suspended in DMEM (Gibco) containing 20% FBS (Gibco) and 250 ng/mL Amphotericin B, 100 U/mL Penicillin, and 100 µg/mL Streptomycin (Gibco). This suspension was placed in a 75T sterile tissue culture flask (Corning). The culture flasks of normal feline soft tissue and the tumor cells were placed in a 37°C, humidified, 5% CO₂ cell culture incubator for approximately 14 days, and the media were refreshed every 3 days. All functional tests were completed within a maximum of the first three passages of the primary cells.

**Validation of antibodies**

Cross-species antibodies (Table 6) including mouse anti-human STAT3 (clone 124H6; Cell Signaling Technology, Danvers, MA, USA), rabbit anti-mouse phospho-STAT3 (Tyr705) (clone D3A7; Cell Signaling Technology, Danvers, MA, USA), rabbit anti-human NF-κB p65 (clone ab86299; Abcam, Cambridge, MA, USA), mouse anti-human α-SMA (clone 1A4; Dako, Glostrup, Denmark), mouse anti-human desmin (clone D33; Dako, Glostrup, Denmark), mouse anti-human cytokeratin (CK) (clone AE1/AE3; Genemed Biotechnologies, Torrance, CA, USA), mouse anti-human vimentin (clone V9; Leica Biosystems, Buffalo Grov, IL, USA), mouse anti-human Melan-A (clone A103; Leica Biosystems, Buffalo Grov, IL, USA), and rabbit anti-human S100 (polyclonal; Leica Biosystems, Buffalo Grov, IL, USA) were used in the present study for characterizing the phenotypes of the FFPE sections and their corresponding primary FISS cell lines. Antibodies for detecting α-SMA, desmin, CK, vimentin, Melan A, and S100 are commonly used for pathological diagnosis in veterinary medicine. The anti-NF-κB p65 antibody, clone ab86299 (Abcam), was characterized and used in our previous study on FISS [20]. Mouse anti-human STAT3 (clone 124H6; Cell Signaling Technology) and rabbit anti-mouse phospho-STAT3 (Tyr705) (clone D3A7; Cell Signaling Technology) have previously been used in feline mammary gland tumor studies [32], and the specificity of both antibodies was confirmed by western blotting in FISS-10 and FISS-14 primary cells (Fig. 5 and Supplementary Fig. 1).

**Preparation of primary FISS cell lysates**

To determine the expression of STAT3 and phospho-STAT3 (Tyr705) in FISS-10 and FISS-14 primary cells, western blotting was performed. The primary cells in a 75T tissue culture flask (Corning) were washed twice with PBS (Gibco), trypsinized with 1 mL of StemPro Accutase Cell Dissociation Reagent (Accutase™, Gibco), and centrifuged at 1000 rpm for 8 min. The supernatant was then discarded. Protein extraction was achieved by incubating the cells in 1 mL of RIPA lysis buffer (VWR Chemicals, Sohn, Ohio, USA) on ice, mixed with cOmplete™ EDTA-free protease inhibitor cocktail (Roche Molecular Biochemicals, Laval, Quebec, Canada), and PhosSTOP™ phosphatase inhibitor (Roche Molecular Biochemicals) for 15 min followed by sonication of the cells in iced water for 20 min. The solution was then centrifuged at 13,000 rpm for 10 min, and the supernatant was stored in aliquots at -20 °C until use.

**Western blotting**

Equal amounts of protein were mixed with an appropriate volume of lithium dodecyl sulfate loading buffer (Invitrogen) in the presence of a reducing agent (50 mM DTT) (Pierce Biotechnology), and the samples were heated in a dry bath at 65 °C for 10 min. The proteins
were then separated on a 10% sodium dodecyl sulfate-polyacrylamide gel (10% resolving gel and 5% stacking gel), blotted onto a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA), and blocked with Block-PRO™ 1 Min Protein-Free Blocking Buffer (Energenesis Biomedical, Taipei City, Taiwan) for 3 min. The blots were probed with antibodies against STAT3 (1:1000 dilution in blocking buffer; Cell Signaling Technology) and phospho-STAT3 (Tyr705) (1:2000 dilution in blocking buffer; Cell Signaling Technology) for 1 h at room temperature and then washed three times with PBS (Gibco). The blots were subsequently incubated using horseradish peroxidase-conjugated secondary anti-rabbit antibody (1:10000 dilution in blocking buffer; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). The protein bands were visualized using the Clarity™ Western ECL Blotting Substrate (Bio-Rad) and detected using the ChemiDoc™ Imaging System (Bio-Rad).

**Immunocytochemistry staining for FISS cells**

ICC staining was used to correlate the phenotypes of primary cell cultures with those of their corresponding FFPE tissue sections. The neoplastic cells and primary cells derived from feline normal soft tissue were fixed in 1:1 100% acetone/100% methanol fixative (Merck, Darmstadt, Germany) for 20 min at -20 °C. The fixed cells were aspirated, and the cells were rinsed twice with PBS. Except for the antibody used for phospho-STAT3 (Tyr705) detection, all antibodies were diluted to their working concentration as listed in Table 6 and applied to the cells for 1 h at room temperature. The antibody specifically targeting phospho-STAT3 (Tyr705) was first diluted to 1:200 and applied to the cells overnight at 4 °C. After the binding of primary antibodies, the cells were washed with PBS 6–10 times and treated with Dako Real Envision-HRP (rabbit/mouse) (Dako Denmark A/S, Glostrup, Denmark) for 60 min at room temperature. After washing with PBS 6–10 times, the reaction products were visualized with 2% diaminobenzidine (Real DAB + chromogen, Dako Denmark A/S, Glostrup, Denmark) for 3 min at room temperature. The cells were counterstained with hematoxylin (Muto Pure Chemicals, Tokyo, Japan) for 10 s. Negative controls were created by omitting the primary antibodies.

**Reagents**

The STAT3 phosphorylation (Tyr705) inhibitor, 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide (LLL12; BioVision Milpitas, CA, USA), a non-peptide, cell-permeable small molecule, was commercially obtained. The LLL12 stock was dissolved in dimethyl sulfoxide (DMSO; Mallinckrodt Chemical Works, St Louis, MO, USA) at 0.01 M.

**Cell proliferation**

The effect of the STAT3 inhibitor LLL12 on the proliferation of primary FISS cells was evaluated using the AlamarBlue Cell Viability Assay Reagent (G-Biosciences, St. Louis, MO, USA). Primary cells derived from feline normal soft tissue, which were not immunoreactive for STAT3, were also used in this assay to evaluate the inhibitory effect of LLL12 (data not shown). Cells at a concentration of 4.5 × 10^5 per well were seeded onto 96 well plates in DMEM supplemented with 10% FBS and incubated at 37 °C overnight. The medium was then removed. After washing twice with PBS, a fresh culture medium (100 µL per well) at various concentrations (0.125, 0.25, 0.5, 1, and 2 µM) of LLL12 was added. The cells in the control group (0 µM) were treated with culture medium alone. The untreated control group was treated with the medium containing DMSO at a concentration equal to the diluent of 2 µM LLL12. The negative control was set up without cells to determine the background fluorescence that might be present. The alamarBlue dye in its oxidized form is blue in color and non-fluorescent. The growing cells cause a chemical reduction of the alamarBlue dye from non-fluorescent blue to fluorescent red. The continued growth of viable cells maintains a reducing environment (fluorescent, red), and the inhibition of growth maintains an oxidized environment (non-fluorescent, blue), which can be detected using a fluorescence or absorbance detector. The media containing the drug were removed, and 100 µL of 10% alamarBlue (G-Biosciences) in PBS was added to each well. After incubation for 3 h at 37 °C, the plate was removed, and the fluorescence was measured at excitation wavelengths of 570 and 595 nm. The percentage reduction of alamarBlue was calculated according to the equation directions provided by the manufacturer and PRISM software (PRISM 6, GraphPad Software, San Diego, CA, USA).

**Cell migration**

Cells at a concentration of 4.5 × 10^4 per well were seeded onto 24-well plates in DMEM supplemented with 1% FBS and incubated at 37 °C overnight. The cells were washed twice with the culture medium. The wounds were generated by scratching the confluent cell monolayer using a pipette tip. The remaining monolayered cells were then treated with LLL12 at concentrations of 2, 1, 0.5, 0.25, 0.125, and 0 µM or DMSO alone as the vehicle control. After washing with culture medium, the wounds were measured and photographed at 0 and 24 h after treatment. Cell migration for the closed distances was measured and compared to that of the control group. The distances were measured in micrometers using ImageJ (NIH, Bethesda, MD, USA). Fifty different measurements per treatment were performed to determine the average distance. The data presented are the averages of triplicate measurements.
Statistical analysis
Comparisons were performed between the treated and untreated groups. Results are expressed as mean ± standard deviation. All statistical tests were performed using SAS version 9.4 (SAS Campus Drive, Cary, NC, USA). The Pearson correlation method was used to examine the correlations between the IHC score of STAT3, phospho-STAT3 (Tyr705), and tumor grading. Statistical significance was set at $P < 0.05$. For the in vitro studies, a one-way analysis of variance was used to analyze the results of the cell proliferation and wound healing assays. Between-group comparisons were performed using Duncan’s multiple range test. Statistical significance was set at $P < 0.05$.

Abbreviations
aFGF: acidic fibroblast growth factor; bFGF: basic fibroblast growth factor; α-SMA: alpha-smooth muscle actin; DIMEM: Dulbecco’s modified Eagle’s medium; JAK: Janus kinase; STAT3: signal transducer and activator of transcription 3; FFPE: formalin-fixed and paraffin-embedded; FISS: Feline injection-site sarcomas; IHC: Immunohistochemistry; ICC: Immunochemistry.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12917-022-03352-y.

Additional file 1.
Additional file 2.

Acknowledgements
Not applicable.

Authors’ contributions
C-H S. has drafted, revised the work, and conducted the experiments; Y-C Lai has revised the work and conducted the experiments; Y-C C. provides specimens and substantial contributions to the conception and analysis, and helps to interpret data; H-Y C. designs the work and approves the submitted version. All authors read and approved the final manuscript.

Funding
This work was supported by the Ministry of Science and Technology, Taiwan, R.O.C. (MOST 107–2313-B-0005-045 to H-Y C).

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to the privacy of the animals used in the study but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All procedures involving animal sample collection were performed in accordance with guidelines of ARRIVE (https://arriveguidelines.org) and Institutional Animal Care and Use Committee of National Taiwan University (NTU, Taiwan), National Chung Hsing University (NCHU) and carried out under the regulation and permission of the IACUC protocol (NTU 107-EL-00165) at NTU and (107-063) at NCHU, respectively.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Graduate Institute of Molecular and Comparative Pathobiology, School of Veterinary Medicine, National Taiwan University, 10617 Taipei, Taiwan.
2Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, 402 Taichung, Taiwan.

Received: 6 January 2022 Accepted: 17 June 2022
Published online: 14 July 2022

References
1. Hendrick MJ. Feline vaccine-associated sarcomas. Cancer Invest. 1999;17(4):273–7.
2. Hendrick MJ, Goldschmidt MH. Do injection site reactions induce fibrosarcomas in cats? J Am Vet Med Assoc. 1991;199(8):968–9.
3. Coyne MJ, Reeves NC, Rosen DK. Estimated prevalence of injection-site sarcomas in cats during 1992. J Am Vet Med Assoc. 1997;210(2):249–51.
4. Doddy FD, Glickman LT, Glickman NW, Janovitz EB. Feline fibrosarcomas at vaccination sites and non-vaccination sites. J Comp Pathol. 1996;114(2):165–74.
5. Hendrick MJ, Brooks JJ. Postvaccinal sarcomas in the cat: histology and immunohistochemistry. Vet Pathol. 1994;31(1):126–9.
6. Kass PH, Spangler WL, Hendrick MJ, McGill LD, Espin DG, Lester S, et al. Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats. J Am Vet Med Assoc. 2003;223(9):1283–92.
7. Kass PH, Barnes WG Jr, Spangler WL, Chomel BB, Culbertson MR. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc. 1993;203(3):396–405.
8. Macy DW, Hendrick MJ. The potential role of inflammation in the development of postvaccinal sarcomas in cats. Vet Clin North Am Small Anim Pract. 1996;26(1):103–9.
9. Blagburn BL, Vaughan JL, Butler JM, Parks SC. Dose titration of an injectable formulation of lufenuron in cats experimentally infested with fleas. Am J Vet Res. 1999;60(12):1513–5.
10. Munday JS, Banyay K, Aberdein D, French AF. Development of an injection site sarcoma shortly after meloxicam injection in an unvaccinated cat. J Feline Med Surg. 2011;13(12):988–91.
11. Martano M, Morello E, Iussich S, Buracco P. A case of feline injection-site sarcoma at the site of cisplatin injections. J Feline Med Surg. 2012;14(10):751–8.
12. Daly MK, Saba CF, Croick SS, Howerton EW, Kosarek CE, Cornell KK, et al. Fibrosarcoma adjacent to the site of microchip implantation in a cat. J Feline Med Surg. 2008;10(2):202–5.
13. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):221–33.
14. Nieto A, Sanchez MA, Martinez E, Rollan E. Immunohistochemical expression of p53, fibroblast growth factor-b, and transforming growth factor-alpha in feline vaccine-associated sarcomas. Vet Pathol. 2003;40(6):651–8.
15. Dubielzig RR, Everett J, Shadduck JA, Albert DM. Clinical and morphologic features of post-traumatic ocular sarcomas in cats. Vet Pathol. 1990;27(1):62–5.
16. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.
17. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011;2:98.
18. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):461–96.
19. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–6.
20. Hseuh CS, Wu CH, Shih CH, Yeh JL, Jeng CR, Pang VF, et al. Role of nuclear factor-kappa B in feline injection site sarcoma. BMC Vet Res. 2019;15(1):365.
21. Sakaguchi M, Oka M, Iwasaki T, Fukami Y, Nishigori C. Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells. J Invest Dermatol. 2012;132(7):1877–85.
22. Fagard R, Metelev V, Souissi S, Baran-Marszak F. STAT3 inhibitors for cancer therapy: Have all roads been explored? J Invest. 2013;2(1):e22882.
23. Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer. 2019;19(2):82–96.

24. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2002;2(6):410–6.

25. Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol. 2005;5(8):593–605.

26. Hughes K, Scase TJ, Foote AK. Estrogen Receptor and Signal Transducer and Activator of Transcription 3 Expression in Equine Mammary Tumors. Vet Pathol. 2015;52(4):631–4.

27. Petterino C, Ratto A, Arciaccia E, Podesta G, Drigo M, Pellegrino C. Expression of Stat3 in feline mammary gland tumours and its relation to histological grade. Vet Res Commun. 2006;30(6):599–611.

28. Hughes K, Scott VHL, Blanck M, Barnett TP, Spanner Kristiansen J, Foote AK. Equine renal hemangiosarcoma: clinical presentation, pathologic features, and pSTAT3 expression. J Vet Diagn Invest. 2018;30(2):268–74.

29. Brown ME, Bear MD, Rosol TJ, Premanandan C, Kisseberth WC, London CA. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet Res. 2015;11:206.

30. Assumpcao A, Jark PC, Hong CC, Lu Z, Ruettten HM, Heaton CM, et al. STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs. J Vet Intern Med. 2018;32(1):361–9.

31. Petterino C, Martano M, Cascio P, Cerruti F, Martini M, Morello E, et al. Immunohistochemical study of STAT3 expression in feline injection-site fibrosarcomas. J Comp Pathol. 2006;134(1):91–100.

32. Petterino C, Podestà G, Ratto A, Drigo M, Pellegrino C. Immunohistochemical study of phospho-Stat3-ser727 expression in feline mammary gland tumours. Vet Res Commun. 2007;31(2):173–84.

33. Yang SF, Wang SN, Wu CF, Teh YT, Chai CY, Chunag SC, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol. 2007;60(6):642–8.

34. Li MX, Bi XY, Huang Z, Zhao JJ, Han Y, Li ZY, et al. Prognostic Role of Phospho-STAT3 in Patients with Cancers of the Digestive System: A Systematic Review and Meta-Analyis. PLoS One. 2015;10(5):e0127356.

35. Macha MA, Marta A, Kaur J, Chauhan SS, Thakar A, Shukla NK, et al. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck. 2011;33(4):482–9.

36. Dennis MM, McSparran KD, Bacon NJ, Schulman FY, Foster RA, Powers BE. Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs. Vet Pathol. 2011;48(1):73–84.

37. Llibarà S, Cecján D, Alafuzoff I. Characteristics of the tissue section that influence the staining outcome in immunohistochemistry. Histochem Cell Biol. 2019;151(1):91–6.

38. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11–9.

39. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–46.

40. Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A. 2005;102(23):8150–5.

41. Bekki H, Kohashi K, Yamada Y, Hirai K, Ishii T, Maekawa A, et al. Phospho-Stat3-tyr727 expression is correlated with histological grade of canine osteosarcoma cell lines. BMC Vet Res. 2012;8:244.

42. Mills SW, Musil KM, Davies JL, Hendrick S, Duncan C, Jackson ML, et al. Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet Pathol. 2015;52(2):238–49.

43. Carneiro CS, de Queiroz GF, Pinto AC, Dagli ML, Materia JM. Feline injection site sarcoma: immunohistochemical characteristics. J Feline Med Surg. 2019;21(4):314–21.

44. Guidice C, Stefanello D, Salla M, Cantatore M, Russo F, Romussi S, et al. Feline injection-site sarcoma: recurrence, tumour grading and surgical margin status evaluated using the three-dimensional histological technique. Vet J. 2010;186(1):84–8.

45. Porcellato I, Menchetti L, Brachelente C, Sforza M, Reginato A, Lepri E, et al. Feline Injection-Site Sarcoma. Vet Pathol. 2017;54(2):204–11.

46. Wei S, Henderson-Jackson E, Qian X, Bui MM. Soft Tissue Tumor Immunohistochemistry Update: Illustrative Examples of Diagnostic Pearls to Avoid Pitfalls. Arch Pathol Lab Med. 2017;141(8):1072–91.

47. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41–51.

48. He G, Karin M. NF-kappaB and STAT3 – key players in liver inflammation and cancer. Cell Res. 2011;21(1):159–68.

49. Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 2010;12(1):39–50.

50. Couto J, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, et al. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC Vet Res. 2012;8:244.

51. Fang P, Hwa V, Rosenfeld RG. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res. 2006;312(8):1229–39.

52. Mandell JW. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem Cell Biol. 2008;130(3):465–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.